Treating Hepatocellular Carcinoma With Sorafenib in Liver Transplant Patients: An Initial Experience

Abstract Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 H...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplantation proceedings 2010-12, Vol.42 (10), p.4582-4584
Hauptverfasser:	Saidi, R.F, Shah, S.A, Rawson, A.P, Grossman, St, Piperdi, B, Bozorgzadeh, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Benzenesulfonates - therapeutic use Biological and medical sciences Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - surgery Combined Modality Therapy Female Fundamental and applied biological sciences. Psychology Fundamental immunology Gastroenterology. Liver. Pancreas. Abdomen Humans Liver Neoplasms - drug therapy Liver Neoplasms - surgery Liver Transplantation Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Niacinamide - analogs & derivatives Phenylurea Compounds Pyridines - therapeutic use Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tissue, organ and graft immunology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.
ISSN:	0041-1345 1873-2623
DOI:	10.1016/j.transproceed.2010.09.147